Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Amtagvi™ is the best-in-class cell therapy treatment for advanced melanoma. The Cell Therapy Account Management (CTAM) will be responsible for driving Amtagvi demand by building a robust referral network between community practices and academic centers; enable early patient identification and streamline referral pathways; and collaborate with internal teams to enhance scientific and operational excellence in cell therapy account management. To succeed in this role, you will use prior experience to optimize territory strategy in the oncology rare disease space and have demonstrated experience influencing others and building relationships. Additional competencies include experience with immunotherapy and solid tumor cancer, as well as prior launch experience, demonstrated ability to drive demand, pull through, and sustain the growth of Amtagvi™.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Senior